Amjad Mehboob

Amjad Mehboob practices at Abbott Northwestern Hospital in Minneapolis, Minnesota, part of Sutter Health.

Amjad Mehboob's NPI, 1396290763, was assigned on August 16, 2016. Amjad Mehboob holds Minnesota license 77392.

Amjad Mehboob's primary practice is Abbott Northwestern Hospital, at 800 East 28th Street, Minneapolis, MN 55407 in Hennepin County. The practice phone is (612) 863-4000.

Amjad Mehboob's primary practice is Abbott Northwestern Hospital in Minneapolis, Minnesota, part of Sutter Health. Amjad Mehboob is also affiliated with United Hospital. The medical group on file is Buffalo Hospital. Dmand AI also links Amjad Mehboob to 2 more hospitals, 2 group practices and clinics, 2 medical groups and 1 home health agency, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Amjad Mehboob practices, 7 sites in all. Vendor and product names are available with a free account.

Nephrology is Amjad Mehboob's primary specialty in the NPI Registry, under taxonomy code 207RN0300X. Amjad Mehboob is licensed in Minnesota.

CMS data shows 174 Medicare services from Amjad Mehboob across 4 procedure codes in 2024, for 62 Medicare patients. Medicare paid $11,428 for them.

CMS counts 62 Medicare patients who saw Amjad Mehboob in 2024. The largest group is 65 to 74, with 27 patients. 75% of them have chronic kidney disease, and 75% have high blood pressure. 24% are also on Medicaid. Their average risk score is 2.94, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Amjad Mehboob's median patient age at 66, with 52% women.

In 2024, Amjad Mehboob wrote 201 Medicare Part D claims for 57 patients. 88% of them were for generic drugs. CMS names the drug for 124 of them, across 7 drugs with 11 or more claims each, at $5,732 in total drug cost. In 2023, CMS named 147 claims across 6 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 86 out of 100 for Amjad Mehboob for performance year 2024, reported as part of a group. Amjad Mehboob accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Amjad Mehboob as offering telehealth.

CMS Open Payments shows 13 general payments to Amjad Mehboob from 6 drug and device companies from 2022 to 2024. Food and beverage make up the largest share, 100% of the total. Calliditas Therapeutics US Inc. paid the most, $98.